Paquinimod

Drug Profile

Paquinimod

Alternative Names: 57-57; ABR-215757; SLE 57-57

Latest Information Update: 29 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Active Biotech
  • Class Amides; Quinolines; Skin disorder therapies; Small molecules
  • Mechanism of Action Calgranulin B modulators; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Systemic scleroderma

Highest Development Phases

  • Suspended Systemic scleroderma
  • Discontinued Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 11 Nov 2016 Suspended - Phase-II for Systemic scleroderma in Germany (PO) (Active Biotech pipeline, November 2016)
  • 11 Nov 2016 Suspended - Phase-II for Systemic scleroderma in Sweden (PO) (Active Biotech pipeline, November 2016)
  • 11 Nov 2016 Suspended - Phase-II for Systemic scleroderma in Switzerland (PO) (Active Biotech pipeline, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top